Eric Gordon
Founder & CEO

Eric B. Gordon
Atentiv, Founder, CEO and Chairman
His vision is to enable every child to better organize and regulate behavior to accomplish goals. Atentiv is a virtual behavioral healthcare clinic in the home, a specialty services provider to primary care in large integrated healthcare delivery networks. ATENTIVmynd™ Solutions provide evidence-based digital medicines with patient centered care that remediate the cause of behavioral disorders -- executive skill dysfunctions -- for health and success in school, home, career and life.

As Founder/CEO, Eric has built eight biopharmaceutical, drug delivery and medical device companies. His success is based on the consistent theme of recognizing early breakthrough scientific concepts and their commercial applications. He has personally invested, developed and executed profoundly impactful development, market and growth strategies. Emerging from his experience is a tested, repeatable model for establishing the strategy, key resources, infrastructure, relationships and financing to enable rapid commercialization, scaling and growth. He has managed multiple products through FDA marketing approval or clearance. He has raised $117M from venture, angel and family office sources, $101M from two IPOs and $660M+ in strategic pharmaceutical company collaborations. Cumulative post money valuations following financings reached $1.7+B. Investor exits on six closed transactions averaged 8.3 times paid-in capital. Two companies reached annual revenues of $500+ and $800+ million.

Over 30+ years, he has co-initiated, driven and managed through full development and/or full global commercialization eight startup companies in behavioral healthcare (Atentiv);in pediatric, adult and traveler's vaccines (Connaught Labs -now Sanofi-Pasteur, and Virogenetics); in combinatorial chemistry for drug discovery (ArQule); in clinical genomics (Ardais); in drug-delivery for endometriosis and PCOD (Combinent); in HDL/CHD therapeutics (Cardium);and ADHD diagnostics (BioBehavioral Diagnostics).

He began his career with Arthur Andersen &Co. and served as VP and CFO at Sterling Drug and General Manager at Glenbrook Labs. Eric holds business degrees from Syracuse University, the University of Pennsylvania, The Wharton School and is a CPA.